← Back to All US Stocks

Vicarious Surgical Inc. (RBOTW) Stock Fundamental Analysis & AI Rating 2026

RBOTW OTC Orthopedic, Prosthetic & Surgical Appliances & Supplies DE CIK: 0001812173
Recently Updated • Analysis: Apr 15, 2026 • SEC Data: 2025-12-31
STRONG SELL
96% Conf
Pending
Analysis scheduled

📊 RBOTW Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: $-45.2M
Current Ratio: 2.97x
Debt/Equity: 0.20x
EPS: $-5.49
AI Rating: STRONG SELL with 96% confidence
Vicarious Surgical Inc. (RBOTW) receives a STRONG SELL rating with 96% confidence from our AI fundamental analysis based on SEC 10-K filings., and return on equity (ROE) of -509.9% Below is our complete RBOTW stock analysis for 2026.

Is Vicarious Surgical Inc. (RBOTW) a Good Investment?

Claude

Vicarious Surgical is a pre-revenue or near-zero revenue company burning approximately $45M in operating cash annually against only $2.6M in cash reserves, creating a critical liquidity crisis. With persistent operating losses of $50M, negative profitability across all metrics, and a cash runway of less than one month at current burn rates, the company faces imminent insolvency without significant capital infusion or immediate path to profitability.

Why Buy Vicarious Surgical Inc. Stock? RBOTW Key Strengths

Claude
  • + Low debt-to-equity ratio of 0.20x provides limited financial flexibility
  • + Operates in surgical supplies sector (SIC 3842) with long-term market potential
  • + Current ratio of 2.97x indicates adequate short-term asset coverage on balance sheet

RBOTW Stock Risks: Vicarious Surgical Inc. Investment Risks

Claude
  • ! No revenue generation reported - company appears pre-commercial or non-viable
  • ! Catastrophic cash burn of $45.1M operating cash flow against $2.6M cash on hand (sub-one-month runway)
  • ! Persistent $50M+ operating losses with zero path to profitability demonstrated
  • ! Negative ROE (-509.9%) and ROA (-256.3%) indicate severe asset utilization failure
  • ! EPS deteriorated 1,325% YoY, signaling worsening financial condition
  • ! Minimal insider activity (2 filings/90 days) suggests limited management confidence

Key Metrics to Watch

Claude
  • * Days of cash remaining and any capital raise announcements
  • * Quarterly revenue achievement or first revenue milestone
  • * Operating cash burn rate trajectory and path to cash flow positive
  • * Form 8-K filings for material adverse changes or going concern warnings

Vicarious Surgical Inc. (RBOTW) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
$-50.2M
EPS (Diluted)
$-5.49
Free Cash Flow
$-45.2M
Total Assets
$19.6M
Cash Position
$2.6M

💡 AI Analyst Insight

Strong liquidity with a 2.97x current ratio provides a solid financial cushion.

RBOTW Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE -509.9%
ROA -256.3%
FCF Margin N/A

RBOTW vs Healthcare Sector: How Vicarious Surgical Inc. Compares

How Vicarious Surgical Inc. compares to Healthcare sector averages

Net Margin
RBOTW 0.0%
vs
Sector Avg 12.0%
RBOTW Sector
ROE
RBOTW -509.9%
vs
Sector Avg 15.0%
RBOTW Sector
Current Ratio
RBOTW 3.0x
vs
Sector Avg 2.0x
RBOTW Sector
Debt/Equity
RBOTW 0.2x
vs
Sector Avg 0.6x
RBOTW Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Vicarious Surgical Inc. Stock Overvalued? RBOTW Valuation Analysis 2026

Based on fundamental analysis, Vicarious Surgical Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-509.9%
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.20x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Vicarious Surgical Inc. Balance Sheet: RBOTW Debt, Cash & Liquidity

Current Ratio
2.97x
Quick Ratio
2.97x
Debt/Equity
0.20x
Debt/Assets
49.7%
Interest Coverage
-2,001.08x
Long-term Debt
$2.0M

RBOTW Revenue & Earnings Growth: 5-Year Financial Trend

RBOTW 5-year financial data:
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Vicarious Surgical Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.04 reflects profitable operations.

RBOTW Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

Vicarious Surgical Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$45.1M
Cash generated from operations
Capital Expenditures
$132.0K
Investment in assets
Dividends
None
No dividend program

RBOTW SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Vicarious Surgical Inc. (CIK: 0001812173)

📋 Recent SEC Filings

Date Form Document Action
Apr 8, 2026 8-K ea0285634-8k_vicarious.htm View →
Mar 23, 2026 DEF 14A ea0282829-def14a_vicarious.htm View →
Mar 9, 2026 8-K ea0280520-8k_vicarious.htm View →
Mar 9, 2026 10-K ea0276827-10k_vicarious.htm View →
Mar 6, 2026 8-K ea0280308-8k_vicarious.htm View →

Frequently Asked Questions about RBOTW

What is the AI rating for RBOTW?

Vicarious Surgical Inc. (RBOTW) has an AI rating of STRONG SELL with 96% confidence, based on fundamental analysis of SEC EDGAR filings.

What are RBOTW's key strengths?

Claude: Low debt-to-equity ratio of 0.20x provides limited financial flexibility. Operates in surgical supplies sector (SIC 3842) with long-term market potential.

What are the risks of investing in RBOTW?

Claude: No revenue generation reported - company appears pre-commercial or non-viable. Catastrophic cash burn of $45.1M operating cash flow against $2.6M cash on hand (sub-one-month runway).

What is RBOTW's revenue and growth?

Vicarious Surgical Inc. reported revenue of N/A.

Does RBOTW pay dividends?

Vicarious Surgical Inc. does not currently pay dividends.

Where can I find RBOTW SEC filings?

Official SEC filings for Vicarious Surgical Inc. (CIK: 0001812173) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is RBOTW's EPS?

Vicarious Surgical Inc. has a diluted EPS of $-5.49.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is RBOTW a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Vicarious Surgical Inc. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is RBOTW stock overvalued or undervalued?

Valuation metrics for RBOTW: ROE of -509.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy RBOTW stock in 2026?

Our dual AI analysis gives Vicarious Surgical Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is RBOTW's free cash flow?

Vicarious Surgical Inc.'s operating cash flow is $-45.1M, with capital expenditures of $132.0K.

How does RBOTW compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -509.9% (avg: 15%), current ratio 2.97 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 15, 2026 | Data as of: 2025-12-31 | Powered by Claude AI